Navigation Links
NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
Date:8/21/2008

SAN DIEGO, Aug. 21 /PRNewswire/ -- NovaRx Corporation announced today that the company initiated its pivotal Phase III clinical trial of Lucanix(R) (belagenpumatucel-L) in the treatment of advanced non-small cell lung cancer (NSCLC). The first patient enrolled in the study was treated by Dr. Lyudmila Bazhenova the trial's principal investigator at the University of California, San Diego School of Medicine.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080821/LATH009-a)

(Photo: http://www.newscom.com/cgi-bin/prnh/20080821/LATH009-b)

The study is designated as the STOP trial because of its expected endpoints: Survival; Tumor-free, Overall; and Progression-free. It is an international, multicenter, randomized, double-blind study involving up to 700 individuals with advanced stage NSCLC, and will be conducted at approximately 90 clinical sites in the U.S., Canada, India, and Europe.

In a Phase II clinical trial, two-year survival among patients with stages IIIB and IV disease who received Lucanix(R) was significantly longer than that of individuals being treated with the current standard of care. A second, investigator-initiated phase II study supported these results.

In contrast to conventional cancer therapies, where systemic chemotherapeutic drugs nonspecifically kill normal cells as well as tumor cells, the therapeutic vaccine developed by NovaRx induces the patient's immune system to specifically target the cancer. In phase II clinical studies to date, the side effects of this treatment have included redness or soreness at the injection site.

"In medical research, you see something like this once in a lifetime," said John Nemunaitis, M.D., executive director at the Mary Crowley Medical Research Center in Dallas, TX and principal investigator of both the
'/>"/>

SOURCE NovaRx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
5. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
6. Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
7. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
8. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
9. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
10. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
11. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... severe flooding that devastated a wide swath of Colorado ... bridges, roads and other infrastructure had been upgraded or ... of Colorado Denver. , "People need to understand the ... associate professor of structural engineering at the CU Denver ... the study. "There is an assumption that a bridge ...
(Date:10/27/2014)... Mass. and TORONTO ... Corporation ( www.generex.com ) (OTCQB: GNBT) today announced ... immunological response triggered by its novel proprietary cancer ... relapse in breast cancer patients. The AE37 cancer ... subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). The ...
(Date:10/27/2014)... Called the NOAH Protocol, this investigative ... of pediatric brain cancer. The implications for groundbreaking ... years of research and development. Amber Larkin, the ... mom's determination can make a difference. , ... it’s only fitting that we’ve received FDA approval ...
(Date:10/27/2014)... -- Investor-Edge has initiated coverage on the ... ), Insmed Inc. (NASDAQ: INSM ), BioCryst ... (NASDAQ: DYAX ), and Oncothyreon Inc. (NASDAQ: ... accessed at: http://investor-edge.com/register . On Friday, ... up 0.69%, the Dow Jones Industrial Average advanced 0.76%, ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... invention from Tel Aviv University a network of tiny ... foil even the most determined intruder. Scattered outdoors on ... of a bank, the dewdrops are a completely new and ... , Prof. Yoram Shapira and his Tel Aviv University Faculty ...
... (R) (lacosamide) C-V, a new antiepileptic drug (AED), ... week of June 2009. Vimpat was approved by ... the use as an add-on therapy for the treatment ... with epilepsy.(Photo: http://www.newscom.com/cgi-bin/prnh/20090526/NY22555 )Vimpat approval is ...
... old man with inoperable lung cancer is able to ... Surgeons told Donald Bickford, 71, that due to ... not an option for removing his lung tumor. To ... Wentworth-Douglass Hospital here, prescribed a type of non-invasive radiosurgery ...
Cached Biology Technology:Intruder alert: Tel Aviv University's 'Smart Dew' will find you! 2Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies 2Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies 3Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 2Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 3
(Date:10/29/2014)... but they also need protection from its harmful rays, just ... in plants that shields them from sun damage. Now, in ... Society , one team reports on the mechanics of how ... at Purdue University note that the harsh ultraviolet radiation plants ... DNA and, as a result, hinder plant growth. Biochemical ...
(Date:10/29/2014)... German . ... Schlögelhofer at the Max F. Perutz Laboratories (MFPL) of ... Vienna dived into the process of meiosis in specific ... inversion of the standard meiotic phases. The researchers describe ... Communications . , Meiosis is the two-step series of ...
(Date:10/29/2014)... October 29, 2014 – Ghrelin is a hormone released ... intake. Alcohol is commonly viewed as a psychoactive substance ... a highly caloric food. , This knowledge, combined ... hypothesis that ghrelin has the potential to stimulate alcohol ... this in humans and found that, as they had ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Ghrelin stimulates an appetite for drinking alcohol 2
... analysis indicates that birds don,t fly alone when migrating at ... journeys, flying in tandem even when they are 200 meters ... University of Illinois and the Illinois Natural History Survey, appears ... is the first to confirm with statistical data what many ...
... numbers of cycles of preimplantation genetic diagnosis or screening ... in 2004 (the most recent year for which data ... a growing number of genetically related conditions, but what ... condition are available for transfer and the parents request ...
... the journal Plant Physiology provides a comprehensive ... the rapidly growing Rosaceae scientific community. ... that comprises more than 3,000 species, including strawberry, apple, ... high-value nutritional foods and they are also the source ...
Cached Biology News:Birds migrate together at night in dispersed flocks, new study indicates 2Birds migrate together at night in dispersed flocks, new study indicates 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3Review article provides tools for the Rosaceae genomics community 2